首页|Data on Biomarkers Reported by Daniella Castro Araujo and Colleagues (Complete b lood count as a biomarker for preeclampsia with severe features diagnosis: a mac hine learning approach)
Data on Biomarkers Reported by Daniella Castro Araujo and Colleagues (Complete b lood count as a biomarker for preeclampsia with severe features diagnosis: a mac hine learning approach)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Diagnostics and Screen ing - Biomarkers is the subject of a report. According to news reporting out of Sao Paulo, Brazil, by NewsRx editors, research stated, “This study introduces th e complete blood count (CBC), a standard prenatal screening test, as a biomarker for diagnosing preeclampsia with severe features (sPE), employing machine learn ing models. We used a boosting machine learning model fed with synthetic data ge nerated through a new methodology called DAS (Data Augmentation and Smoothing).” Our news journalists obtained a quote from the research, “Using data from a Braz ilian study including 132 pregnant women, we generated 3,552 synthetic samples f or model training. To improve interpretability, we also provided a ridge regress ion model. Our boosting model obtained an AUROC of 0.90±0.10, sensitivity of 0.9 5, and specificity of 0.79 to differentiate sPE and non-PE pregnant women, using CBC parameters of neutrophils count, mean corpuscular hemoglobin (MCH), and the aggregate index of systemic inflammation (AISI). In addition, we provided a rid ge regression equation using the same three CBC parameters, which is fully inter pretable and achieved an AUROC of 0.79±0.10 to differentiate the both groups. Mo reover, we also showed that a monocyte count lower than yielded a sensitivity of 0.71 and specificity of 0.72. Our study showed that ML-powered CBC could be use d as a biomarker for sPE diagnosis support. In addition, we showed that a low mo nocyte count alone could be an indicator of sPE. Although preeclampsia has been extensively studied, no laboratory biomarker with favorable cost-effectiveness h as been proposed.”
Sao PauloBrazilSouth AmericaBiomar kersCyborgsDiagnostics and ScreeningEmerging TechnologiesHealth and Medi cineMachine LearningObstetricsPreeclampsiaPregnancy ComplicationsWomen ’s Health
NETL
NSTL
